GSK JV wins FDA approval for HIV drug

|By:, SA News Editor

GlaxoSmithKline (GSK) joint venture company ViiV Healthcare has won FDA approval for its once-daily HIV pill Tivicay.

In a trial released last year, a combination of Tivicay and other antiretroviral drugs reduced the HIV virus to undetectable levels in more people than Gilead's (GILD) Atripla, the world's top-selling treatment in the field. Another rival drug is Merck's (MRK) Isentress, whose sales last year were $1.5B.

GlaxoSmithKline owns 76.5% of ViiV, Pfizer (PFE) 13.5% and Japan's Shionogi 10%.